EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Ckd Bio (063160) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Ckd Bio KRW 2,197, price KRW 12,820, upside -82.9%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7063160006

CB Thin data Sep 24, 2026

Ckd Bio

063160 · KO

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Weakest SetupStrongly overvalued and low quality.

!Fair value 2,197 KRW · Strongly overvalued (−83%)
!Quality 39/100
!Expensive Growth (revenue 5y +5.1 %/yr)
!Thin margins · 6.5% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/10)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
!Weak on past: 22 out of 100
!Weak on dividend: 15 out of 100
Watch Ckd Bio for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

76,542 KRW 12,430 KRW Fair Value 2,197 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 12,430 KRW – 76,542 KRW · fair‑value band 1,617 KRW – 2,674 KRW · the 12,820 KRW price screens above the 2,197 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Ckd Bio in your weekly email

Every Wednesday you see whether Ckd Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally.

Show more

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Stock analysis

Ckd Bio (063160) currently trades at 12,820 KRW, while our model-based Fair Value estimate is 2,197 KRW, implying the stock looks roughly 483.4% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 17,615 KRW per share, and 3 of the 9 models we run sit above the 12,820 KRW price.

Bear case: the Dividend Discount group reads lowest at 944.54 KRW, and 6 of the 9 models stay below the price. Evidence for this calculation is low.

Scenario range: 1,617 KRW (bear) to 2,674 KRW (bull), the price of 12,820 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ckd Bio reported revenue of 160B KRW in FY2025 versus 142B KRW in FY2021, a compound +3.0%/yr. Reported net income was −2.9B KRW in FY2025.

Key figures

Market cap 70.3B KRW (≈ $51.7M) · P/S ratio 0.58 · Dividend yield 0.8% · Net margin −1.8% · Return on equity 5.6% · Return on assets (EBIT) −2.1% · Operating margin −13.4% · Revenue (TTM) 125B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).

What moves the price

The share trades about 47% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −83%, 063160 screens richer than that median.

Fair Value models

Bear 1,617 KRW Fair Value 2,197 KRW Bull 2,674 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 12,869 KRW 17,615 KRW 23,107 KRW 77
EPV 1,340 KRW 1,847 KRW 2,259 KRW 74
ROIC Compounder 1,340 KRW 1,847 KRW 2,259 KRW 72
All 9 models by family
DCF Models
Owner Earnings 12,869 KRW 17,615 KRW 23,107 KRW 77
Earnings-Based
EPV 1,340 KRW 1,847 KRW 2,259 KRW 74
Dividend Discount
Gordon GGM 696.55 KRW 1,035 KRW 1,339 KRW 69
DDM Multi-Stage 696.55 KRW 944.54 KRW 1,165 KRW 67
Multiples
EV/EBIT 5,494 KRW 8,287 KRW 11,080 KRW 65
EV/EBITDA 33,978 KRW 46,266 KRW 58,554 KRW 67
EV/Revenue 3,096 KRW 5,659 KRW 8,222 KRW 52
Asset-Based
NCAV (Graham) 11,578 KRW 15,515 KRW 23,157 KRW 54
Economic Profit
ROIC Compounder 1,340 KRW 1,847 KRW 2,259 KRW 72

Open the full fair value analysis →

Notify me when 063160 reaches fair value

Put 063160 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 39/100

Of which business quality 36 · Market factors (momentum, volatility) 26

Profitability 16
Margins and returns on capital today
Quality Growth 15
Are margins and returns improving?
Cashflow 23
Earnings quality: real cash, not paper profit
Fin. Strength 22
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 8
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.1% (2020) → 2.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

063160 screens 483% overvalued. Compare with Merck KGaA →

Compare Ckd Bio with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −83% · Bottom 25%
Profitability
Return on equity (TTM) 6% · Below median
Return on assets 3% · Below median
Net margin (TTM) 6% · Below median
Operating margin (TTM) −13% · Bottom 25%
Growth and dividend
Revenue growth 13% · Above median
Dividend yield (TTM) 0.8% · Below median
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

EV/EBITDA 0.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)63 · sector 20
PAST (return on equity)22 · sector 27
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)15 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ckd Bio · Fair Value
2,197 KRW −483%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Ckd Bio Fair Value". https://www.fairvalue-calculator.com/stock/063160

Frequently asked questions

Is Ckd Bio (063160) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,197 KRW versus a price of 12,820 KRW, about −83% upside (overvalued).
What is the fair value of 063160?
Our model-based fair value for Ckd Bio is 2,197 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 12,820 KRW.
What is the quality score of 063160?
Ckd Bio has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ckd Bio (063160)?
Our model-based price target is the fair value of 2,197 KRW (as of Sep 24, 2026) from 9 valuation models. Cautious scenario 1,617 KRW, optimistic scenario 2,674 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Ckd Bio stock forecast for 2026?
Our models put fair value at 2,197 KRW, about −83% upside versus a price of 12,820 KRW (overvalued). Cautious scenario 1,617 KRW, optimistic scenario 2,674 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Ckd Bio (063160)?
Ckd Bio reported trailing-twelve-month revenue of about 125B KRW (latest available figure, as of Sep 24, 2026).
Does Ckd Bio pay a dividend?
Ckd Bio currently shows a dividend yield of about 0.75% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Ckd Bio (063160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ckd Bio it is 2,197 KRW per share (as of Sep 24, 2026), against a price of 12,820 KRW. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Ckd Bio stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 063160 trades above its calculated fair value: price 12,820 KRW, fair value 2,197 KRW, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 063160?
No. The price is what the market pays today (12,820 KRW); the fair value is what the company's own numbers justify (2,197 KRW). For Ckd Bio the two are 10,623 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Ckd Bio worth?
The market values Ckd Bio at about 70.3B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 12,820 KRW; our models calculate a fair value of 2,197 KRW per share.
What do the bullish and bearish scenarios say about 063160?
Our models span a range for Ckd Bio: cautious scenario 1,617 KRW, base 2,197 KRW, optimistic 2,674 KRW per share (as of Sep 24, 2026, price 12,820 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ckd Bio (063160)?
Balance-sheet figures for Ckd Bio (as of Sep 24, 2026): return on equity 5.6%, debt of 0.14 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 063160 from its 52-week high?
Ckd Bio trades at 12,820 KRW, about 47% below its 52-week high of 24,100 KRW and 3% above the low of 12,430 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,197 KRW is for.
Which stocks are comparable to Ckd Bio?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ckd Bio stock attractive at the current price?
The data as of Sep 24, 2026: price 12,820 KRW, calculated fair value 2,197 KRW (−83%), Quality Score 39/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 063160 calculated?
We run Ckd Bio through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,197 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Ckd Bio itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ckd Bio (063160)?
The closing price on Sep 23, 2026 was 12,820 KRW. Our model-based fair value is 2,197 KRW, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ckd Bio right now?
The price sits above even our optimistic bull case (2,674 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Ckd Bio

How large is the market capitalisation of Ckd Bio (063160)?
The market capitalisation of Ckd Bio is 70.3B KRW (≈ $51.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ckd Bio (063160)?
The price-to-sales ratio of Ckd Bio is 0.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Ckd Bio (063160)?
The dividend yield of Ckd Bio is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ckd Bio (063160)?
The net margin of Ckd Bio is −1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ckd Bio (063160)?
The return on equity (ROE) of Ckd Bio is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ckd Bio (063160)?
On an EBIT basis the return on assets of Ckd Bio is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ckd Bio (063160)?
The operating margin of Ckd Bio is −13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ckd Bio (063160)?
Revenue at Ckd Bio is growing +12.6% versus a year earlier (3y avg +0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ckd Bio (063160)?
Earnings per share at Ckd Bio are growing −86.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ckd Bio (063160) generate?
The free cash flow of Ckd Bio is −11.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ckd Bio (063160) carry?
The net debt of Ckd Bio is 141B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ckd Bio in the live analysis

One click puts Ckd Bio on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.